A Study on the Prevalence of the Modified Citrullinated Vimentin Anti-body (Anti-MCV) in an Irish Rheumatoid Arthritis (RA) Population and to Assess the Impact of Anti-MCV and the Anti-cyclic-citrullinated Peptide Antibody (Anti-CCP) Status on the Management of Irish Patients With Early RA

NCT01078597 · clinicaltrials.gov ↗
COMPLETED
Status
35
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

AbbVie (prior sponsor, Abbott)

Collaborators